Stifel Nicolaus Trims Qiagen (NYSE:QGEN) Target Price to $45.00

Qiagen (NYSE:QGEN) had its target price lowered by Stifel Nicolaus from $55.00 to $45.00 in a report issued on Wednesday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Several other equities research analysts also recently issued reports on QGEN. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an overweight rating in a research note on Thursday, February 8th. Morgan Stanley raised Qiagen from an equal weight rating to an overweight rating and boosted their price target for the stock from $49.48 to $51.00 in a research report on Friday, February 16th. Finally, Citigroup dropped their target price on Qiagen from $61.86 to $60.00 and set a buy rating on the stock in a research report on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $50.95.

Qiagen Stock Performance

NYSE:QGEN opened at $42.98 on Wednesday. The company has a market cap of $9.81 billion, a price-to-earnings ratio of 28.85, a price-to-earnings-growth ratio of 3.61 and a beta of 0.42. The company has a quick ratio of 1.62, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.70. The company has a fifty day simple moving average of $42.53 and a two-hundred day simple moving average of $42.75.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The firm had revenue of $459.00 million during the quarter, compared to analysts’ expectations of $453.91 million. During the same quarter in the prior year, the business earned $0.53 EPS. Qiagen’s quarterly revenue was down 5.4% compared to the same quarter last year. As a group, equities analysts anticipate that Qiagen will post 2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC boosted its holdings in shares of Qiagen by 21.6% in the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock valued at $58,000 after purchasing an additional 237 shares during the period. Xponance Inc. raised its holdings in shares of Qiagen by 2.7% in the fourth quarter. Xponance Inc. now owns 9,609 shares of the company’s stock valued at $417,000 after acquiring an additional 253 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after acquiring an additional 283 shares during the period. CWM LLC increased its position in Qiagen by 19.1% during the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock valued at $96,000 after purchasing an additional 358 shares during the period. Finally, Signaturefd LLC lifted its position in shares of Qiagen by 9.0% in the 3rd quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock worth $190,000 after purchasing an additional 385 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.